Data-driven analysis in drug discovery

Journal of Receptors and Signal Transduction

Volumn 26, Issue 4, 2006, Pages 299-327

  Kenakin, Terry ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Drug discovery; Measurement of agonist response; Measurement of antagonism; Receptor theory

Indexed keywords

NEW DRUG;

AGONIST; ALLOSTERISM; ARTICLE; CONFORMATIONAL TRANSITION; DISSOCIATION CONSTANT; DRUG ANTAGONISM; DRUG BINDING; DRUG EFFICACY; DRUG MANUFACTURE; DRUG POTENCY; DRUG POTENTIATION; EQUILIBRIUM CONSTANT;

ALLOSTERIC REGULATION; ALLOSTERIC SITE; BINDING, COMPETITIVE; CHEMISTRY, PHARMACEUTICAL; COMPUTATIONAL BIOLOGY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ANTAGONISM; DRUG DESIGN; DRUG INDUSTRY; HUMANS; KINETICS; LIGANDS; MODELS, BIOLOGICAL;

EID: 33745824256     PISSN: 10799893     EISSN: 15324281     Source Type: Journal    
DOI: 10.1080/10799890600778300     Document Type: Article

References (18)

1. Black JW, Leff P. Operational models of pharmacological agonists. Proc Soc Lond Biol 1983, 220, 141-162.
2. 2-adrenergic receptor: Extending the ternary complex model. J Biol Chem 1993, 268, 4625-4636.
3. Weiss JM, Morgan PH, Lutz MW, Kenakin TP. The cubic ternary complex receptor-occupancy model. I. Model description. J Theor Biol 1996, 178, 151-167.
4. Weiss JM, Morgan PH, Lutz MW, Kenakin TP. The cubic ternary complex receptor-occupancy model. II. Understanding apparent affinity J Theor Biol 1996, 178, 169-182.
5. Weiss JM, Morgan PH, Lutz MW, Kenakin TP. The cubic ternary complex receptor-occupancy model. III. Resurrecting Efficacy. J Theor Biol 1996, 181, 381-397.
6. Gaddum JH. The quantitative effects of antagonistic drugs. J Physiol Lond 1937, 89, 7P-9P.
7. Arunlakshana O, Schild HO. Some quantitative uses of drug antagonists., Br J Pharmacol 1959, 14, 48-58.
8. 2 values and associated analysis. J Pharmacol Exp Ther 1978, 207, 705-718.
9. Lew MJ, Angus JA. Analysis of competitive agonist-antagonist interactions by non-linear regression. Trends Pharmacol Sci 1996, 16, 328-337.
10. Ehlert FJ. Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. Mol Pharmacol 1988, 33, 187-194.
11. Christopolous A, Kenakin TP. G-protein coupled receptor allosterism and complexing. Pharmacol Rev 2002, 54, 323-374.
12. Stephenson RP. A modification of receptor theory. Br J Pharmacol 1956, 11, 379-393.
13. Kaumann AJ, Marano M. On equilibrium dissociation constants for complexes of drug receptor subtypes. Selective and non-selective interactions of partial agonists with two β-adrenoceptor subtypes mediating positive chronotropic effects of (-) isoprenaline in kitten atria. Naunyn Schmiedebeberg's Arch Pharmacol 1982, 219, 216-221.
14. Paton WDM, Rang HP. The uptake of atropine and related drugs by intestinal smooth muscle of the guinea pig in relation to acetylcholine receptors. Proc R Soc Lond Biol 1965, 163, 1-44.
15. Gaddum JH, Hameed KA, Hathway DE, Stephens FF. Quantitative studies of antagonists for 5-hydroxytryptamine. Q J Exp Physiol 1955, 40, 49-74.
16. Jakubic J, Bacakova L, Lisa V, El-Fakahany EE, Tucek S. Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. Mol Pharmacol 1997, 52, 172-179.
17. Maeda K, Nakata H, Koh Y, Miyakawa T, Ogata H, Takaoka Y, Sbibayama S, Sagawa K, Fukushima D, Moravek J, et al. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro. J Virol 2004, 78, 8654-8662.
18. Watson C, Jenkinson S, Kazmierski W, Kenakin TP. The CCR5 Receptor-based mechanism of action of 873140, a potent allosteric non-competitive HIV entry-inhibitor. Mol Pharmacol 2005, 67, 1268-1282.